Pfizer says its COVID-19 pill cut hospitalization and death by nearly 90%
WASHINGTON — Pfizer said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% as the drugmaker joins the race to bring the first easy-to-use medication against the disease to the U.S. market.
Currently, all COVID-19 treatments used in the U.S. require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and Britain on Thursday became the first country to authorize its use.
Pfizer said it would ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.
If it’s authorized, the company would sell the drug under the brand name Paxlovid.Researchers worldwide have been racing to find a pill against COVID-19 that can be taken at home to ease symptoms, speed recovery and reduce the crushing burden on hospitals and doctors.
AdvertisementPfizer released preliminary results Friday of its study of 775 adults. Patients taking the company’s drug along with another antiviral had an 89% reduction in their combined rate of hospitalization or death after a month, compared to patients taking a dummy pill. Fewer than 1% of patients taking the drug needed to be hospitalized, and no one died. In the comparison group, 7% were hospitalized, and there were seven deaths.
“We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90% efficacy and 100% protection for death,” Dr. Mikael Dolsten, Pfizer’s chief scientific officer, said in an interview.
News credit : www.latimes.com